Dr. David Bledsoe is expert in all phases of veterinary pharmaceutical development and has spent the majority of his career leading clinical research products for FDA, Center for Veterinary Medicine (CVM) regulated products.  He is experienced in all FDA-CVM regulations regarding drug development, Good Laboratory Practices (GLP), Good Clinical Practices (GCP), Good Manufacturing Practices (GMP) and pharmacosurveillance.

​David’s career is a mix of working in Industry and in private practice as a veterinarian.  The later part of his career has been in Industry working for both large and small animal health companies before working as a consultant.  He currently consults with the Scullion Strategy Group and he is also the Managing Director of Qualitas BioSciences, LLC.  Prior to consulting, he was the Director of Clinical Research at Nutramax Laboratories, the Vice President of Specialty Practice at Animal Clinical Investigation (ACI) and was the R&D Project Manager at Central Life Sciences, formerly Farnam Companies. He also held field veterinary positions for companies such as, Bayer Animal Health and Novartis Animal Health.  

Prior to joining the veterinary pharmaceutical industry, he had had several roles in private practice in the state of New Hampshire in small animal and emergency medicine.

David has taken formal short courses in Veterinary and Comparative Pharmacokinetics, GLPs for Study Directors and Monitors, and managing Compliant Veterinary Clinical Trials (GCPs), as well as being media trained.  David enjoys writing, both professionally, as a technical writer, and personally.  He has been privileged to work with some of the leading researchers in several clinical areas and his list of publications is extensive.  Outside of drug development, his areas of clinical interest include veterinary behavior, dermatology, internal medicine, parasitology, pain management and models of anti-nociception.

David is a member of American Veterinary Medical Association, the American Academy of Veterinary Dermatology, the and was a former board member of the National Commission on Veterinary Economic Issues  Sponsor’s Council. He is also Board Member at Large for Not One More Vet, Inc, (NOMV) a peer-to-peer support group for veterinarians dedicated to mental health and wellness in the veterinary profession. David is also an Administrator for NOMV’s 15,000 member Facebook page.

Although David resides in Arizona, he still maintains a veterinary license in the state of New Hampshire.  He holds a Doctorate in Veterinary Medicine from Virginia Polytechnic Institute and State University in Blacksburg, VA and a Bachelor of Science in Biology from Frostburg State University in Frostburg, MD.

 

For additional information visit:  https://www.linkedin.com/in/david-l-bledsoe-dvm-167b2811/

 

Publications:

Enomoto M, Kigin PD, Bledsoe D, Slone R, Hash J, Smith CE, Lascelles BD. Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product. BMC Vet Res. 2017 Jan 24;13(1):32.

Tomas A, Bledsoe D, Wall S, Davidson G, Lascelles BD. Initial evaluation of a canine stifle arthrotomy post-operative pain model. Vet J. 2015 Jun; 204(3):293-8.

DePorter T, Landsberg G, Araujo J, Ethier J, Bledsoe D. Harmonease Chewable Tablets reduces noise-induced fear and anxiety in a laboratory canine thunderstorm simulation: A blinded and placebo-controlled study. Journal Veterinary Behavior. Vol, 7(4): 225-232, July 2012.

Papich M, Davis J, Chen A, Bledsoe, D. Tramadol pharmacokinetics in dogs and in Vitro-in Vivo correlation of an oral extended release tablet. Proceedings, 25th Annual Forum, American College of Veterinary Internal Medicine, Seattle, WA. June 9, 2007.

Papich M, Bledsoe D. Tramadol pharmacokinetics in cats after oral administration of an immediate release tablet. Proceedings, 25th Annual Forum, American College of Veterinary Internal Medicine, Seattle, WA. June 9, 2007.

Blagburn BL, Spencer JA, Billeter SA, Drazenovich NL, Butler JM, Land TM, Dykstra CC, Stafford KC, Pough MB, Levy SA, Bledsoe DL. Use of imidacloprid – permethrin to prevent transmission of Anaplasma phagocytophilum from naturally infected Ixodes scapularis ticks to dogs. Veterinary Therapeutics; 5(3): 212 – 217, Fall 2004.

Spencer JA, Butler JM, Stafford KC, Pough MB, Levy SA, Bledsoe DL, Blagburn BL. Evaluation of permethrin and imidacloprid for prevention of Borrelia burgdoferi transmission from blacklegged ticks (Ixodes scapularis) to Borrelia burgdorferi-free dogs. Parasitology Research; 90 Suppl 3:S106-7, 2003.

Schroeder I, Blagburn BL, Bledsoe DL, Bond R, Denholm I, Dryden MW, Jacobs DE, Mehlhorn H, Mencke N, Payne P, Rust MK, Vaughn MB. Progress of the international work of the imidacloprid flea susceptibility monitoring team. Parasitology Research; 90 Suppl 3:S127-128, 2003.

Blagburn BL, Spencer JA, Butler JM, Stafford KC, Pough MB, Levy SA, Bledsoe DL (presenter). Evaluation of permethrin + imidacloprid for prevention of Borrelia burgdorferi transmission from blacklegged ticks (Ixodes scapularis) to Borrelia burgdorferi-free dogs. Proceedings 19th meeting of the World Association for the Advancement of Veterinary Parasitology, New Orleans, LA; August 10 – 14, 2003.

Dryden MW, Blagburn BL, Bledsoe DL, Bond R, Denholm I, Jacobs DE, Mehlhorn H, Mencke N, Payne P, Rust M, Schroeder I, Vaughn M. Imidacloprid (Advantage) international flea susceptibility monitoring: update 2003. Proceedings American Association of Veterinary Parasitologists, 48th Annual Meeting, Denver, CO; July 19 – 22, 2003.

Spencer JA, Butler JM, Stafford KC, Pough MB, Levy SA, Bledsoe DL, Blagburn BL. Evaluation of permethrin + imidacloprid for prevention of Borrelia burgdorferi transmission from blacklegged ticks (Ixodes scapularis) to Borrelia burgdorferi-free dogs. Proceedings American Association of Veterinary Parasitologists, 48th Annual Meeting, Denver, CO; July 19 – 22, 2003.

Spencer JA, Butler JM, Stafford KC, Pough MB, Levy SA, Bledsoe DL, Blagburn BL. Evaluation of permethrin + imidacloprid for prevention of Borrelia burgdorferi transmission from blacklegged ticks (Ixodes scapularis) to Borrelia burgdorferi-free dogs. Proceedings 7th International Symposium on Ectoparasites of Pets, League City, TX; April 13 – 16, 2003.

Dryden MW, Payne P, Blagburn BL, Bledsoe DL, Denholm I, Hansen O, Hinkle NC, Hopkins T, Jacobs DE, Mehlhorn H, Mencke N, Rust MK, Schroeder I, Vaughn MB. Establishment of susceptibility profiles of cat fleas to imidacloprid and development of a program to monitor for imidacloprid susceptibility among cat flea populations – a 2002 update. Suppl. Compend. Cont. Educ. Pract. Vet., 24 (4B): 14 – 18, 2002.

Rust MK, Waggoner M, Hinkle NC, Mencke N, Hansen O, Vaughn M, Dryden MW, Payne P, Blagburn B, Jacobs DE, Bach T, Bledsoe D, Hopkins T, Mehlhorn H. Development of a bioassay for susceptibility of cats fleas (Siphonaptera: Pulicidae) to imidacloprid. Journal of Medical Entomology, Vol. 39, no. 4, 671 – 674, 2002.

Blagburn BL, Bach T, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE, Mehlhorn H, Mencke N, Rust MK, Vaughn MB. Advantage international flea susceptibility monitoring initiative – a 2001 update. Suppl. Cont. Educ. Pract. Vet., 23 (4A): 4 – 7, 2001.

Denholm I, Bach T, Blagburn BL, Bledsoe DL, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE , Mehlhorn H, Mencke N, Rust MK, Vaughn MB. Proactive monitoring of changes in susceptibility to imidacloprid in the cat flea, Ctenocephalides felis. Proceedings, Resistance 2001: Meeting the Challenge, IACR, Rothamsted, September 24 – 26, 2001. (Abstract).

Jacobs DE, Bach T, Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Mehlhorn H, Mencke N, Rust MK, Vaughn MB. An international flea susceptibility monitoring initiative. Proceedings, World Assoc. Advance. Vet. Parasitol. Stresa, Italy, August 2001, p. 199.

Vaughn MB, Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE, Mehlhorn H, Mencke N, Rust MK. Imidacloprid (Advantage) international flea susceptibility monitoring: Update 2001 and outlook. In: Proceedings. 46th Ann. Meet. Amer. Assoc. Vet. Parasitol, Boston, MA, July, 2001. P. 30 – 31.

Dryden MW, Blagburn BL, Bach T, Bledsoe DL, Denholm I, Hansen O, Hinkle NC, Hopkins T, Jacobs DE , Mehlhorn H, Mencke N, Rust MK, Vaughn MB. In vitro susceptibility of four laboratory strains of cat flea, Ctenocephalides felis. In: Proceedings 46th Ann. Meet. Amer. Assoc. Vet. Parasitol, Boston, MA, July, 2001. P. 31.

Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE , Mehlhorn H, Mencke N, Rust MK, Vaughn MB. In vitro susceptibility to imidacloprid of 17 field-collected isolates of the cat flea, Ctenocephalides felis. Proceedings 46th Ann. Meet. Amer. Assoc. Vet. Parasitol, Boston, MA, July, 2001. P. 32.

Hansen O, Bach T, Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hinkle NC, Hopkins T, Jacobs DE , Mehlhorn H, Mencke N, Rust MK, Vaughn MB. Larval bioassay: A reference test to determine susceptibility of fleas to imidacloprid? Proceedings 6th International Symposium Ectoparasites Pets, Westport, Ireland, May 2001.

Bach T. Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE, Mehlhorn H, Mencke N, Payne P, Rust MK, Vaughn MB. Susceptibility of Ctenocephalides felis larvae to imidacloprid: close response bioassay. Proceedings of Australian Society for Parasitology. 2001. (Abstract)

Everett R, Cunningham J, Arther R, Bledsoe D, Mencke N. Comparative evaluation of the speed of flea kill of imidacloprid and selamectin on dogs. Veterinary Therapeutics, Vol. 1, No. 4, Fall 2000.

Dryden MW, Blagburn BL, Bledsoe DL, Denholm I, Hansen O, Hinkle NC, Hopkins T, Jacobs DE, Mehlhorn H, Mencke N, Rust MK, Vaughn MB. Susceptibility of cat fleas to control agents: development of a monitoring system. Proceedings 45th Ann. Meet. Am. Assoc. Vet. Parasitol. Salt Lake City, Utah, July 2000. P. 36.

Denholm I, Blagburn BL, Bledsoe DL, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE, Mehlhorn H, Mencke N, Rust MK, Vaughn MB. Prospects for combating insecticide resistance in cat fleas (Ctenocephalides felis): Lessons from other pests. Proceedings 45th Ann. Meet. Am. Assoc. Vet. Parasitol. Salt Lake City, Utah, July 2000.

Jacobs DE, Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Mehlhorn H, Mencke N, Rust MK, Vaughn MB. Development of bioassays to determine flea susceptibility to an insecticide: standardization of laboratory methods. Proceedings 45th Ann. Meet. Am. Assoc. Vet. Parasitol. Salt Lake City, Utah, July 2000.

Rust MK, Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE , Mehlhorn H, Mencke N, Vaughn MB. Bioassay results of laboratory raised and field-collected strains of the cat flea (Ctenocephalides felis). Proceedings 45th Ann. Meet. Am. Assoc. Vet. Parasitol. Salt Lake City, Utah, July 2000.

Blagburn BL, Bledsoe DL, Denholm I, Dryden MW, Hansen O, Hinkle NC, Hopkins T, Jacobs DE , Mehlhorn H, Mencke N, Rust MK, Vaughn MB. Flea resistance, a perspective from veterinary parasitology. Proceedings 45th Ann. Meet. Am. Assoc. Vet. Parasitol. Salt Lake City, Utah, July 2000.

Bledsoe DL (invited presentation) The Advantage International Susceptibility Monitoring Project, 4th World Congress of Veterinary Dermatology, San Francisco, CA, August 31, 2000.

David Bledsoe, DVM 

Product Development Strategy & Project Management

5820 N. Church Street, Suite D#213, Greensboro, NC 27455 | 336.209.4941
  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon

By using this site you agree that we can place cookies on your device. See our Privacy Policy and Cookie Policy for details.

© 2019 Scullion Strategy Group, LLC. All Rights Reserved.